Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598508 | 0.85 | PIK3CD (0.53) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL1887862 | 0.85 | MEN1 (0.48) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL1884319 | 0.85 | PIK3CD (0.47) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL3386976 | 0.82 | PIK3CD (0.46) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL1597713 | 0.81 | PIK3CD (0.65) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL28539195 | 0.80 | PDE10A (0.62) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL1598030 | 0.80 | PIK3CD (0.49) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL3654574 | 0.80 | PIK3CD (0.44) | L3MBTL1DRD4DRD3PIK3CDATM | |
| SCHEMBL1878444 | 0.79 | PIK3CD (0.51) | L3MBTL1DRD4DRD3PIK3CDATM | |
| Formic Acid SCHEMBL1887914 | 0.78 | PIK3CD (0.45) | L3MBTL1DRD4DRD3PIK3CDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231641-B1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-06-01 | — | — | EP | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | L3MBTL1 3240/4885DRD4 3720/4885DRD3 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.